The risks of developing other common Lynch-associated cancers, such as ovarian, gastric, and small bowel cancers, are generally significantly higher for carriers of pathogenic MLH1 and MSH2 variants compared to those for individuals harboring pathogenic mutations in the MSH6 and PMS2 genes. This evidence concerns the gene MLH1 and small intestine carcinoma.